Overview

Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma

Status:
Active, not recruiting

Trial end date:
2025-02-01

Target enrollment:

Participant gender:

Summary

This study, with 20 patients participating, will examine the safety and tolerability for the ipilimumab/UV1 combination in patients with unresectable or metastatic malignant melanoma.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Ultimovacs AS
Ultimovacs ASA

Collaborator:

Oslo University Hospital

Treatments:

Antibodies, Monoclonal
Ipilimumab
Vaccines